In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster session 3: Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
Session

Congress : EHRA 2019

Topic : Other

  • Session type : Poster Session
  • Date : 19 March 2019
  • Time : 08:30 - 12:30

18 presentations in this session

Association between ventricular fibrillation recurrences and chest compressions in out-of-hospital cardiac arrest

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : F Guerra (Ancona,IT)

Clinical impact on ventricular arrhythmic risk of serum free thyroxine concentration in euthyroid patients with structural heart diseases

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : H Makimoto (Duesseldorf,DE)

Precedent non-sustained ventricular tachycardias predicts subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : H Makimoto (Duesseldorf,DE)

P-wave morphology and risk of sudden cardiac death in patients with coronary artery disease

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : J Perkiomaki (Oulu,FI)

10-year trends in the use of catheter ablation for the treatment ofVT versus other ablation procedures and PCI for the treatment of IHD

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : R Anderson (Melbourne,AU)

Predictive role of invasive electrophysiological study in patients with active vs. previous myocarditis

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : G Peretto (Milan,IT)

Risk factors for ventricular arrhythmias in cardiac-variant fabry disease

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : F Varian (Sheffield,GB)

Does the level advancement of coronary artery disease predicts the appearance of ventricular arrhythmia?

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : E Gadula-Gacek (Zabrze,PL)

Case control analysis shows high burden of CASQ2 variants in a large cohort of sudden arrhythmic death syndrome victims

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : B Gray (London,GB)

Early repolarization pattern in children: differences between Caucasian and North-Malagasy population

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : A Creta (Roma,IT)

Impact of cardiac tachyarrhtythmias recorded in Coronary Intensive Care Unit (CICU) on short and long-term mortality and duration of CICU hospitalization

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : P Papakonstantinou (Athens,GR)

Periodic repolarization dynamics and risk of sudden cardiac death in patients with stable coronary artery disease

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : A Kiviniemi (Oulu,FI)

Characterisation of sudden death circumstances in young adults. Insights from a 6-year web-based Italian study.

Congress : EHRA 2019

  • Session : Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
  • Speaker : A Baccelli (Lucca,IT)

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are